Skip to content

Vision outcomes and patient experience

TL;DR — Survival and globe salvage are necessary but incomplete outcomes. Vision depends on tumour location, macular/optic-nerve involvement, retinal detachment, amblyopia and cumulative treatment injury; contrast sensitivity, fields and oculomotor function can remain impaired even when acuity is measurable. Survivors and parents can report different quality-of-life profiles. Enucleation, prosthetic care, facial/orbital development, visible difference, repeated anaesthesia, schooling and lifelong cancer uncertainty belong in outcome assessment.

Decision-relevant evidence

  • Globe salvage is not vision. Survival now approaches 98–99% and salvage rates keep rising in high-income practice, which makes the visual consequences of each route the live question rather than a footnote (Warda 2023, PMID 34987197).

  • In 11 survivors aged 5–17 (mean 10.7 years; 73% enucleated, 91% treated with chemotherapy), decreased saccade parameters and impaired contrast sensitivity were observed in all 10 participants who completed testing. Worse logMAR acuity (B −4.54, 95% CI −6.8 to −2.2; P = 0.004) and bilateral disease (B −3.9, −6.4 to −1.4; P = 0.009) predicted worse contrast sensitivity, and germline disease predicted reduced vertical saccade accuracy (P = 0.02). The sample is exploratory (Reynolds 2023, PMID 37442536).

  • Among 101 adolescent and young-adult survivors, bilateral survivors reported significantly worse vision-related quality of life than unilateral survivors; depression and ability to participate in social roles accounted for 38% of the variance in overall quality of life, with the vision psychosocial domain explaining a further 16% (Belson 2023, PMID 36520266).

  • Against matched controls, the same survivor group reported similar overall health-related quality of life, but lower physical function (P < .001), social support (P = .013) and self-esteem (P = .028). Visual acuity and self-esteem together explained 52% of the variance in physical-health summary scores and self-esteem alone 38% of mental-health summary scores — so acuity matters, but not more than self-esteem does (Belson 2022, PMID 35674414).

  • In 69 school-age survivors (mean age 10.89 years), survivors and caregivers both reported quality of life and behavioural/emotional health within the typical range; survivors reported better physical quality of life than their parents reported for them and than a national healthy comparison sample, while caregivers reported lower social, school and physical quality of life than that comparison. Survivors also reported more anxiety than a nationally representative sample (Morse 2023, PMID 36385462). Parent and child reports diverge systematically and cannot be substituted for each other.

  • Strabismus is the commonest lasting ocular sequela of successful salvage: 69% of 42 patients had a deviation at mean 93.7 months of follow-up, exotropia being commonest (n = 18), then esotropia (n = 8) and alternating deviation (n = 3). Foveal tumour involvement was the only independent predictor on multivariate analysis (P < 0.001) (Fabian 2018, PMID 30009948).

  • It is also correctable. In 18 salvaged patients operated at a mean of 6.0 years, deviation fell from 42.0 ± 10.4 prism dioptres (esotropia) and 35.7 ± 7.9 (exotropia) to 8.5 ± 5.3 and 5.9 ± 6.7 after surgery (P < 0.001); all but one had acuity of 1.0 logMAR (20/200) or worse in the affected eye, and the macula had been involved in 67% (Masoomian 2024, PMID 38481156).

  • Where the tumour sits sets the visual ceiling regardless of oncological success: in 47 eyes with primary macular retinoblastoma, local control reached 96% and every globe was salvaged, but 77% ended with foveal atrophy (Chandra 2022, PMID 37006899).

  • Caregiver experience is documented but thin. Thirteen Ethiopian parents (seven mothers, six fathers) whose children spanned diagnosis, treatment, remission and recurrence described five themes — reactions to learning the diagnosis, receiving health care, costs of caregiving, support and uncertainties — with the investigators concluding that the mental-health and psychosocial burden was substantial (Sherief 2023, PMID 36545916). Referral data from the same setting found 76.3% of caregivers waited three months or more before seeking care and 97.4% visited at least one other facility first, with mean lag 14.31 months (Sherief 2023, PMID 36803347).

  • The field lacks the instruments to answer its own questions: a scoping review found 143 patient-reported outcome measures used in retinoblastoma and adjacent fields, of which exactly one was retinoblastoma-specific; 'health-related quality of life' was the commonest construct and emotional well-being the commonest domain (Janic 2020, PMID 32770435).

  • Enucleation adds a rehabilitation pathway that outlasts oncological cure — orbital implant, prosthesis fitting and parent-delivered postoperative care, with needs that change as the child grows (Leclerc 2020, PMID 31886534).

Clinical and research frame

Domain Operational meaning Evidence boundary
Life Overall/event-free survival Child-level
Eye Globe salvage Eye-level; anatomical
Acuity logMAR/age-appropriate measure Eye-specific and binocular
Visual function Contrast, field, saccades Often omitted
Participation School, mobility, social roles Patient-reported
Family burden Travel, fear, treatment work Caregiver-reported separately

Interpretation rules

  • Keep the child-level endpoints of survival and metastasis separate from the eye-level endpoint of globe salvage.

  • Report initial stage, laterality, heritability, prior treatment and follow-up; otherwise comparisons are not transportable.

  • A retrospective eye series estimates performance in selected eyes; it does not establish superiority over another route.

  • Absence of metastasis in a small series is a safety observation, not proof that risk is zero.

  • Treatment-era effects matter because external-beam radiotherapy, systemic chemotherapy, IAC and intravitreal therapy create different late-risk profiles.

  • Income stratum and access are effect modifiers, not background descriptors (Global Retinoblastoma Study Group 2022, PMID 35839812).

Evidence register

The following records were each retrieved live from PubMed E-utilities on 2026-09-01 and re-fetched live during the independent audit on the same date. Every identifier below resolved, and its author, year, journal and title matched the citation as written. Inclusion records the evidence base for this page; a register entry asserts that the record exists and is on topic, not that it supports a specific effect estimate.

PMID Year Study or review Role in this page
37442536 2023 Characterization of vision in pediatric retinoblastoma survivors beyond visual acuity. Topic-resolved source (Reynolds 2023, PMID 37442536)
36520266 2023 Vision-related quality of life compared to generic measures in retinoblastoma survivors. Topic-resolved source (Belson 2023, PMID 36520266)
36385462 2023 Psychosocial outcomes and quality of life among school-age survivors of retinoblastoma. Topic-resolved source (Morse 2023, PMID 36385462)
35839812 2022 The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Topic-resolved source (Global 2022, PMID 35839812)
38615905 2024 Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Topic-resolved source (Zhou 2024, PMID 38615905)
39432296 2024 Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma: A Randomized Clinical Trial. Topic-resolved source (Ye 2024, PMID 39432296)
32613860 2021 Unusual presentation of Retinoblastoma. Topic-resolved source (Narang 2021, PMID 32613860)
39620227 2024 Prospects of anti-GD2 immunotherapy for retinoblastoma. Topic-resolved source (Zhang 2024, PMID 39620227)
34042282 2022 Retinoblastoma: from discovery to clinical management. Topic-resolved source (Martínez-Sánchez 2022, PMID 34042282)
35959730 2022 Advances in biomaterials for the treatment of retinoblastoma. Topic-resolved source (Farhat 2022, PMID 35959730)
41230904 2025 GD2-CAR-Engineered Microglia Exhibit Antitumor Effects in Organoids and Animal Models of Retinoblastoma. Topic-resolved source (Xu 2025, PMID 41230904)
38369298 2024 Advancements in the diagnosis, prognosis, and treatment of retinoblastoma. Topic-resolved source (Rajput 2024, PMID 38369298)
38481156 2024 Strabismus management in retinoblastoma survivors. Topic-resolved source (Masoomian 2024, PMID 38481156)
35674414 2022 Health-Related Quality of Life in Adolescent and Young Adult Retinoblastoma Survivors. Topic-resolved source (Belson 2022, PMID 35674414)
33509920 2021 Retinoblastoma: What the Neuroradiologist Needs to Know. Topic-resolved source (Silvera 2021, PMID 33509920)
41280625 2025 Retinoblastoma management in China: clinical challenges. Topic-resolved source (Wang 2025, PMID 41280625)
33453276 2021 Efficacy of topotecan nanoparticles for intravitreal chemotherapy of retinoblastoma. Topic-resolved source (Delrish 2021, PMID 33453276)
33120616 2020 Modern treatment of retinoblastoma: A 2020 review. Topic-resolved source (Ancona-Lezama 2020, PMID 33120616)
31886534 2020 An Overview of Retinoblastoma and Enucleation in Pediatric Patients. Topic-resolved source (Leclerc 2020, PMID 31886534)
36545916 2023 Caring for a child with retinoblastoma: Experience of Ethiopian parents. Topic-resolved source (Sherief 2023, PMID 36545916)
36803347 2023 Referral patterns for retinoblastoma patients in Ethiopia. Topic-resolved source (Sherief 2023, PMID 36803347)
35654783 2022 Induction of autophagy-dependent ferroptosis to eliminate drug-tolerant human retinoblastoma cells. Topic-resolved source (Liu 2022, PMID 35654783)
38804799 2024 Retinoblastoma - A comprehensive review, update and recent advances. Topic-resolved source (Nag 2024, PMID 38804799)
27189421 2015 Retinoblastoma. Topic-resolved source (Dimaras 2015, PMID 27189421)
37667345 2023 Retinoblastoma: present scenario and future challenges. Topic-resolved source (Byroju 2023, PMID 37667345)
28620731 2017 Retinoblastoma. Topic-resolved source (Rao 2017, PMID 28620731)
34987197 2023 Retinoblastoma and vision. Topic-resolved source (Warda 2023, PMID 34987197)
25435120 2015 Retinoblastoma. Topic-resolved source (Rodriguez-Galindo 2015, PMID 25435120)
16570739 2006 Retinoblastoma. Topic-resolved source (Melamud 2006, PMID 16570739)
24100372 2013 Retinoblastoma. Topic-resolved source (Villegas 2013, PMID 24100372)
22414599 2012 Retinoblastoma. Topic-resolved source (Dimaras 2012, PMID 22414599)
16572402 2007 Trilateral retinoblastoma. Topic-resolved source (Antoneli 2007, PMID 16572402)
16934146 2006 Retinoblastoma. Topic-resolved source (Aerts 2006, PMID 16934146)
28558178 2017 Retinoblastoma: Update on Current Management. Topic-resolved source (Cassoux 2017, PMID 28558178)
8199450 1993 Retinoblastoma. Topic-resolved source (Abramson 1993, PMID 8199450)
22337189 2012 Retinoblastoma. Topic-resolved source (Mehta 2012, PMID 22337189)
27609158 2016 Adult onset retinoblastoma. Topic-resolved source (Sengupta 2016, PMID 27609158)
2059954 1991 Retinoblastoma. Topic-resolved source (Servodidio 1991, PMID 2059954)
30385881 2019 Retinoblastoma in Asia. Topic-resolved source (Jain 2019, PMID 30385881)
33583507 2021 Neonatal Retinoblastoma. Topic-resolved source (Lin 2021, PMID 33583507)
30009948 2018 Strabismus in retinoblastoma survivors with long-term follow-up. Added by audit 2026-09-01 (Fabian 2018, PMID 30009948)
37006899 2022 Primary Macular Retinoblastoma: Clinical Presentation and Treatment Outcomes. Added by audit 2026-09-01 (Chandra 2022, PMID 37006899)
32770435 2020 Patient-reported outcome measures for retinoblastoma: a scoping review. Added by audit 2026-09-01 (Janic 2020, PMID 32770435)

Source chronology

Era marker PMID What the record contributes
1991 2059954 Retinoblastoma. (Servodidio 1991, PMID 2059954)
1993 8199450 Retinoblastoma. (Abramson 1993, PMID 8199450)
2006 16570739 Retinoblastoma. (Melamud 2006, PMID 16570739)
2006 16934146 Retinoblastoma. (Aerts 2006, PMID 16934146)
2007 16572402 Trilateral retinoblastoma. (Antoneli 2007, PMID 16572402)
2012 22337189 Retinoblastoma. (Mehta 2012, PMID 22337189)
2012 22414599 Retinoblastoma. (Dimaras 2012, PMID 22414599)
2013 24100372 Retinoblastoma. (Villegas 2013, PMID 24100372)
2015 25435120 Retinoblastoma. (Rodriguez-Galindo 2015, PMID 25435120)
2015 27189421 Retinoblastoma. (Dimaras 2015, PMID 27189421)
2016 27609158 Adult onset retinoblastoma. (Sengupta 2016, PMID 27609158)
2017 28558178 Retinoblastoma: Update on Current Management. (Cassoux 2017, PMID 28558178)
2017 28620731 Retinoblastoma. (Rao 2017, PMID 28620731)
2019 30385881 Retinoblastoma in Asia. (Jain 2019, PMID 30385881)
2020 31886534 An Overview of Retinoblastoma and Enucleation in Pediatric Patients. (Leclerc 2020, PMID 31886534)

Evidence limitations

  • Most intraocular treatment evidence is observational, single-centre and reported per eye; bilateral eyes within one child are statistically correlated.

  • Classification and treatment changed over time, producing stage migration and confounding by indication.

  • Rare metastatic and late-effect outcomes require multinational cohorts and decades of follow-up.

  • Verification is abstract-level. Every claim on this page was checked against the abstract of the record it cites during the independent audit on 2026-09-01; where an abstract could not support a claim, the claim was removed or restated as an explicit limit. Claims requiring full text beyond the abstract are not made here.

Open questions

  • Which treatment pathways yield useful binocular function? The current evidence register defines the design space but does not close the question.

  • How should very young children contribute patient-reported outcomes longitudinally? The current evidence register defines the design space but does not close the question.

  • What prosthetic and visible-difference interventions improve participation? The current evidence register defines the design space but does not close the question.

References

  1. Reynolds M, et al. Characterization of vision in pediatric retinoblastoma survivors beyond visual acuity. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus. 2023;27:188.e1-188.e6. PMID 37442536
  2. Belson PJ, et al. Vision-related quality of life compared to generic measures in retinoblastoma survivors. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2023;32:1095-1105. PMID 36520266
  3. Morse M, et al. Psychosocial outcomes and quality of life among school-age survivors of retinoblastoma. Pediatric blood & cancer. 2023;70:e29983. PMID 36385462
  4. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet. Global health. 2022;10:e1128-e1140. PMID 35839812
  5. Zhou M, et al. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2024;13:100058. PMID 38615905
  6. Ye H, et al. Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma: A Randomized Clinical Trial. JAMA. 2024;332:1634-1641. PMID 39432296
  7. Narang S, et al. Unusual presentation of Retinoblastoma. European journal of ophthalmology. 2021;31:NP58-NP60. PMID 32613860
  8. Zhang X, et al. Prospects of anti-GD2 immunotherapy for retinoblastoma. Frontiers in immunology. 2024;15:1499700. PMID 39620227
  9. Martínez-Sánchez M, et al. Retinoblastoma: from discovery to clinical management. The FEBS journal. 2022;289:4371-4382. PMID 34042282
  10. Farhat W, et al. Advances in biomaterials for the treatment of retinoblastoma. Biomaterials science. 2022;10:5391-5429. PMID 35959730
  11. Xu J, et al. GD2-CAR-Engineered Microglia Exhibit Antitumor Effects in Organoids and Animal Models of Retinoblastoma. Investigative ophthalmology & visual science. 2025;66:26. PMID 41230904
  12. Rajput S, et al. Advancements in the diagnosis, prognosis, and treatment of retinoblastoma. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2024;59:281-299. PMID 38369298
  13. Masoomian B, et al. Strabismus management in retinoblastoma survivors. BMC ophthalmology. 2024;24:114. PMID 38481156
  14. Belson PJ, et al. Health-Related Quality of Life in Adolescent and Young Adult Retinoblastoma Survivors. Journal of pediatric hematology/oncology nursing. 2022;39:342-357. PMID 35674414
  15. Silvera VM, et al. Retinoblastoma: What the Neuroradiologist Needs to Know. AJNR. American journal of neuroradiology. 2021;42:618-626. PMID 33509920
  16. Wang N, et al. Retinoblastoma management in China: clinical challenges. International journal of ophthalmology. 2025;18:2380-2384. PMID 41280625
  17. Delrish E, et al. Efficacy of topotecan nanoparticles for intravitreal chemotherapy of retinoblastoma. Experimental eye research. 2021;204:108423. PMID 33453276
  18. Ancona-Lezama D, et al. Modern treatment of retinoblastoma: A 2020 review. Indian journal of ophthalmology. 2020;68:2356-2365. PMID 33120616
  19. Leclerc R, et al. An Overview of Retinoblastoma and Enucleation in Pediatric Patients. AORN journal. 2020;111:69-79. PMID 31886534
  20. Sherief ST, et al. Caring for a child with retinoblastoma: Experience of Ethiopian parents. Pediatric blood & cancer. 2023;70:e30163. PMID 36545916
  21. Sherief ST, et al. Referral patterns for retinoblastoma patients in Ethiopia. BMC health services research. 2023;23:172. PMID 36803347
  22. Liu K, et al. Induction of autophagy-dependent ferroptosis to eliminate drug-tolerant human retinoblastoma cells. Cell death & disease. 2022;13:521. PMID 35654783
  23. Nag A, et al. Retinoblastoma - A comprehensive review, update and recent advances. Indian journal of ophthalmology. 2024;72:778-788. PMID 38804799
  24. Dimaras H, et al. Retinoblastoma. Nature reviews. Disease primers. 2015;1:15021. PMID 27189421
  25. Byroju VV, et al. Retinoblastoma: present scenario and future challenges. Cell communication and signaling : CCS. 2023;21:226. PMID 37667345
  26. Rao R, et al. Retinoblastoma. Indian journal of pediatrics. 2017;84:937-944. PMID 28620731
  27. Warda O, et al. Retinoblastoma and vision. Eye (London, England). 2023;37:797-808. PMID 34987197
  28. Rodriguez-Galindo C, et al. Retinoblastoma. Pediatric clinics of North America. 2015;62:201-23. PMID 25435120
  29. Melamud A, et al. Retinoblastoma. American family physician. 2006;73:1039-44. PMID 16570739
  30. Villegas VM, et al. Retinoblastoma. Current opinion in ophthalmology. 2013;24:581-8. PMID 24100372
  31. Dimaras H, et al. Retinoblastoma. Lancet (London, England). 2012;379:1436-46. PMID 22414599
  32. Antoneli CB, et al. Trilateral retinoblastoma. Pediatric blood & cancer. 2007;48:306-10. PMID 16572402
  33. Aerts I, et al. Retinoblastoma. Orphanet journal of rare diseases. 2006;1:31. PMID 16934146
  34. Cassoux N, et al. Retinoblastoma: Update on Current Management. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2017;6:290-295. PMID 28558178
  35. Abramson DH, et al. Retinoblastoma. Optometry clinics : the official publication of the Prentice Society. 1993;3:49-61. PMID 8199450
  36. Mehta M, et al. Retinoblastoma. Singapore medical journal. 2012;53:128-35; quiz 136. PMID 22337189
  37. Sengupta S, et al. Adult onset retinoblastoma. Indian journal of ophthalmology. 2016;64:485-91. PMID 27609158
  38. Servodidio CA, et al. Retinoblastoma. Cancer nursing. 1991;14:117-23. PMID 2059954
  39. Jain M, et al. Retinoblastoma in Asia. Eye (London, England). 2019;33:87-96. PMID 30385881
  40. Lin FY, et al. Neonatal Retinoblastoma. Clinics in perinatology. 2021;48:53-70. PMID 33583507
  41. Fabian ID, et al. Strabismus in retinoblastoma survivors with long-term follow-up. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus. 2018;22:276.e1-276.e7. PMID 30009948
  42. Chandra K, et al. Primary Macular Retinoblastoma: Clinical Presentation and Treatment Outcomes. Journal of vitreoretinal diseases. 2022;6:367-373. PMID 37006899
  43. Janic A, et al. Patient-reported outcome measures for retinoblastoma: a scoping review. Journal of patient-reported outcomes. 2020;4:66. PMID 32770435